Lilly to acquire ICOS in $2.1 billion deal

Share this article:
Eli Lilly has agreed to purchase ICOS, co-marketer of erectile dysfunction drug Cialis (tadalfil), for approximately $2.1 billion. Lilly and ICOS have been partners in Cialis since 1998 and launched the drug together in 2003, capturing 25% of the ED market in the US. “This transaction provides financial and operation al benefits to Lilly,” said CEO Sidney Taurel in a statement. “We also look forward to further developing the commercial potential of tadalfil through the pursuit of new indications.” The deal is expected to close in late 2006 or early 2007, with positive earnings results by 2008. In July, Lilly reported Cialis sales jumped 22% in the second quarter to $233.2 million. Lilly is scheduled to report its third quarter results Thursday.
Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...